Category Archives : Allgemein

Home  >>  Allgemein

DKFZ: Drug against psoriasis slows down cancer cell growth and metastasis

On August 12, 2016, Posted by , In Allgemein, With No Comments

Scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) are examining a promising agent against cancer of the immune system. In this type of cancer, the tumor cells have lost their ability to respond to signals that cause programmed cell death, or apoptosis. The new substance restores this ability,…

Heidelberg University: „Gummy Bear“ Versus Needle: New Manufacturing Process for Peptide and Protein Drugs

On Juli 18, 2016, Posted by , In Allgemein, With No Comments

Team of young Heidelberg researchers receives EXIST start-up grant A team of young Heidelberg researchers has been approved for funding from the EXIST Transfer of Research programme for a new process to manufacture specific active ingredients that in future will allow oral administration instead of painful injections. The innovative process…

Affimed Reports Financial Results for First Quarter 2016

On Mai 18, 2016, Posted by , In Allgemein, With No Comments

Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today reported financial results for the quarter ended March 31, 2016. “IO combination therapies, like our lead drug AFM13 in combination with our partner Merck’s Keytruda, may offer a similarly high efficacy…

Merck and Pfizer Announce First Patient Treated in Phase III Combination Study with Avelumab and INLYTA® in Renal Cell Carcinoma

On April 5, 2016, Posted by , In Allgemein, With No Comments

Darmstadt, Germany, and New York, US, April 5, 2016 – Merck and Pfizer (NYSE: PFE) today announced the treatment of the first patient in a Phase III study of avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in an advanced renal cell carcinoma (RCC) setting. The study, JAVELIN Renal…

Affimed Appoints Dr. Joerg Windisch as Chief Operating Officer and Adds Dr. Bernhard Ehmer to Supervisory Board

On Januar 21, 2016, Posted by , In Allgemein, With No Comments

Heidelberg, Germany, January 21, 2016 -­ Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced the appointment of Dr. Joerg Windisch to the position of Chief Operating Officer. As COO, Dr. Windisch will provide his broad expertise in pharmaceutical regulatory affairs, quality control…

Glycotope names Paul G Higham as new Chief Executive Officer

On Januar 7, 2016, Posted by , In Allgemein, With No Comments

Glycotope GmbH, a global leader in glyco-optimization of biopharmaceuticals, today announced the appointment of Paul G Higham as its new Chief Executive Officer (CEO), effective immediately. “We are excited to further strengthen the Management Team of Glycotope through the appointment of Paul G Higham, a seasoned healthcare industry leader with…

Affimed Announces Appointment of Andrew Curtis to Lead Corporate Strategy and Business Development, Expansion of US Presence

On Dezember 2, 2015, Posted by , In Allgemein, With No Comments

Link: http://www.affimed.com/pdf/20151202_andrew_hired_final.pdf

Heidelberg University: Lifestyle Change Could Reduce Risk of Alzheimer’s

On November 4, 2015, Posted by , In Allgemein, With No Comments

Heidelberg ageing researchers study connection between cholesterol level and cognitive decline in old age Changes in lifestyle could reduce the risk of developing Alzheimer’s disease. That was the conclusion of a study conducted by researchers of Heidelberg University’s Network Aging Research (NAR), who examined the data from two independent epidemiological…

University of Copenhagen joins European health elite

On August 27, 2015, Posted by , In Allgemein, With No Comments

Copenhagen (Denmark) – Knowledge, growth and visions for future health. These will be the keywords when the University of Copenhagen formally becomes part of the strategic alliance ‚Health Axis Europe‘ on Thursday 27 August 2015 at 14.00. The alliance collaborates on sharing resources across Europe and strengthening the competitiveness through…

DKFZ: Fatty acid increases performance of cellular powerhouse – Fundamentally new biological signaling pathway discovered

On Juli 28, 2015, Posted by , In Allgemein, With No Comments

Scientists from the German Cancer Research Center (DKFZ) have discovered an entirely new control mechanism that regulates the function of mitochondria, the powerhouses of the cell. Surprisingly, a fatty acid is playing a key role in this process. The scientists have now reported in the journal Nature that using fatty…